AstraZeneca's David Brennan - CEO Pay
David Brennan - AstraZeneca
Total Compensation: $4.7M
Details: So much for those rumors that Brennan turned down a double-digit pay increase. The CEO's compensation bounced back from 2007's 19 percent drop, with his total 2008 salary of £2.51 million ($4.7 million) coming in at a 17 percent increase over 2007. Brennan's base salary dropped from 2007's $2 million to 1.8 million in 2008, but his bonus jumped from $2,016,000 to $2,425,000. He also received $406,000 in allowances, which included a car, relocation funds and cash for a vested performance share plan award.
AstraZeneca News:
AZ's Brennan sees "top-line" challenges ahead
AstraZeneca - Top 5 layoffs of 2008
AZ nabs more uses for Seroquel XR
AZ's Brennan tries to conceal Crestor glee
AZ's expanded China focus pays off
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: